Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026
Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Company Deals Digital

Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics

Fineline Cube Jul 21, 2026
Policy / Regulatory

China Launches 12th Batch of National Drug Procurement with Vonoprazan and Vitamin B6 Drawing Record Competition

Fineline Cube Jul 21, 2026
Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Fineline Cube Jul 22, 2026
Company Drug

Junshi Biosciences Receives NMPA Acceptance for Toripalimab Expanded Indication in Resectable Stage II–III NSCLC

Fineline Cube Jul 22, 2026
Company Drug

Merck’s HER3-Targeted ADC Patritumab Deruxtecan Faces FDA Complete Response Letter

Fineline Cube Jun 27, 2024

Merck, Sharp & Dohme Inc. (NYSE: MRK), a leading U.S. pharmaceutical company, has announced that...

Company Drug

Moderna’s RSV Vaccine Efficacy Wanes to 50% After 18 Months, Shares Slide

Fineline Cube Jun 27, 2024

Moderna Inc. (NASDAQ: MRNA), a U.S.-based biopharmaceutical company, has announced long-term efficacy data for its...

Company Deals

CASI Pharmaceuticals Secures USD 15 Million in PIPE Transaction for Anti-CD38 Monoclonal Antibody Development

Fineline Cube Jun 27, 2024

CASI Pharmaceuticals (NASDAQ: CASI), a biopharmaceutical company based in China, has announced the signing of...

Company Drug

J&J Halts Mid-Stage Trial for Tremfya in Giant Cell Arteritis Due to Efficacy Concerns

Fineline Cube Jun 26, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a leading U.S.-based healthcare company, has reportedly discontinued a...

Company Drug

AstraZeneca’s Tagrisso Wins NMPA Approval for First-Line EGFR-mutated NSCLC Treatment

Fineline Cube Jun 26, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical company, has announced that it has received another...

Company Deals

Sanofi Invites Bids Starting at $20 Billion for Consumer Health Unit

Fineline Cube Jun 26, 2024

Sanofi (NYSE: SNY) is reportedly inviting bids starting at USD 20 billion for its consumer...

Policy / Regulatory

China’s NMPA Proposes Expedited Review for Clinically Urgent Overseas Drugs

Fineline Cube Jun 26, 2024

The National Medical Products Administration (NMPA) has released a draft proposal titled “Announcement of the...

Company Deals Digital R&D

Eli Lilly & Co. Partners with OpenAI to Use Generative AI in Antimicrobial Drug Discovery

Fineline Cube Jun 26, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has...

Company Deals

Aidea Pharmaceutical to Boost Stake in Nanda Pharmaceutical to 51.1256%

Fineline Cube Jun 26, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, is poised...

Company Drug

Sino Biopharmaceutical Gains NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes

Fineline Cube Jun 26, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a major player in China’s pharmaceutical industry, has announced that...

Company Drug

CSPC Pharmaceutical’s BCMA-Targeted CAR-T Therapy SYS6020 Receives NMPA Clinical Trial Approval

Fineline Cube Jun 26, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Novo Nordisk’s Semaglutide for Long-Term Weight Management Receives NMPA Approval

Fineline Cube Jun 26, 2024

Novo Nordisk (NYSE: NVO, CPH: NOVO-B), a leading healthcare company from Denmark, has announced that...

Company Drug

Jiangsu Simcere Pharmaceutical Wins NMPA Nod for Biosimilar Version of Erbitux

Fineline Cube Jun 26, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096), a Chinese pharmaceutical company, has announced that it...

Company Deals

Walvax Biotechnology Halts COVID-19 mRNA Vaccine Trials Co-Developed with Abogen Biosciences

Fineline Cube Jun 26, 2024

Walvax Biotechnology Co., Ltd (SHE: 300142), a biopharmaceutical company based in China, has announced the...

Company Policy / Regulatory

U.S. Lawmakers Question FDA on Discrepancies in Foreign Inspections of China and India

Fineline Cube Jun 25, 2024

U.S. lawmakers have intensified their scrutiny of the FDA’s foreign inspection program, particularly for companies...

Company

Novo Nordisk to Pump USD 4.1 Billion into U.S. Manufacturing Expansion

Fineline Cube Jun 25, 2024

Novo Nordisk (NYSE: NVO), a Danish biopharmaceutical company, has announced plans to invest USD 4.1...

Company Drug

Merck KGaA’s Xevinapant Misses Primary Endpoint in Phase III Head and Neck Cancer Trial

Fineline Cube Jun 25, 2024

Merck KGaA (NYSE: MRK), a leading German pharmaceutical company, has encountered a setback in the...

Company Deals

Suzhou Porton Biologics Becomes First Chinese CDMO to Adopt MaxCyte’s ExPERT GTx Platform

Fineline Cube Jun 25, 2024

Suzhou Porton Biologics Ltd, a biopharmaceutical company based in China, has announced the introduction of...

Company Drug

J&J’s Tecvayli Earns NMPA Approval for Relapsed or Refractory Multiple Myeloma

Fineline Cube Jun 25, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a leading U.S. healthcare company, has announced that it...

Company Drug

Alebund Pharmaceuticals’ AP306 Earns Breakthrough Designation for Chronic Kidney Disease

Fineline Cube Jun 25, 2024

Alebund Pharmaceuticals, based in Shanghai, has announced that its drug candidate AP306 (EOS789), a pan-inhibitor...

Posts pagination

1 … 372 373 374 … 698

Recent updates

  • Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II
  • TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal
  • Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications
  • Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody
  • Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Zepbound and Mounjaro in GLP-1 Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.